Novo Nordisk A/S (NYSE:NVO) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 68.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 99,183 shares of the company's stock after selling 219,357 shares during the quarter. Segall Bryant & Hamill LLC's holdings in Novo Nordisk A/S were worth $8,532,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of NVO. ICW Investment Advisors LLC increased its stake in shares of Novo Nordisk A/S by 1.2% during the fourth quarter. ICW Investment Advisors LLC now owns 41,142 shares of the company's stock worth $3,539,000 after acquiring an additional 472 shares during the period. Woodmont Investment Counsel LLC raised its stake in shares of Novo Nordisk A/S by 276.2% during the 4th quarter. Woodmont Investment Counsel LLC now owns 110,551 shares of the company's stock worth $9,510,000 after buying an additional 81,163 shares in the last quarter. Congress Wealth Management LLC DE raised its stake in shares of Novo Nordisk A/S by 7.8% during the 4th quarter. Congress Wealth Management LLC DE now owns 18,079 shares of the company's stock worth $1,555,000 after buying an additional 1,303 shares in the last quarter. Dillon & Associates Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.4% in the 4th quarter. Dillon & Associates Inc. now owns 287,476 shares of the company's stock valued at $24,723,000 after buying an additional 4,059 shares during the period. Finally, Mosley Wealth Management boosted its stake in shares of Novo Nordisk A/S by 22.2% in the fourth quarter. Mosley Wealth Management now owns 4,912 shares of the company's stock valued at $413,000 after buying an additional 892 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

Several research analysts have issued reports on the company. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded down $0.81 during trading hours on Friday, hitting $69.36. The company's stock had a trading volume of 5,852,065 shares, compared to its average volume of 5,563,763. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business has a fifty day moving average of $82.33 and a 200-day moving average of $98.64. Novo Nordisk A/S has a twelve month low of $69.18 and a twelve month high of $148.15. The stock has a market cap of $311.23 billion, a price-to-earnings ratio of 21.08, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.